lusvertikimab subcutaneous / OSE Immunotherapeutics - LARVOL DELTA

Expected Value Inflection Points over OSE’s three-year strategic plan (2026-2028) (GlobeNewswire) - "H1 2027: Lusvertikimab sub-cutaneous formulation readiness; H2 2027: Possible start of Ulcerative Colitis Phase 2b/3....2028: Lusvertikimab 1st Phase 2 read-out in pouchitis or hidradenitis suppurativa."

New P2/3 trial • P2 data • Hidradenitis Suppurativa • Ulcerative Colitis